Jowell Global Ltd. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; the filing text does not provide a clear Q4-only results breakdown. Financial statements are prepared under U.S. GAAP. The company operates a China-focused e-commerce and retail business through a variable interest entity (VIE).
Business context and financial results
Jowell sells cosmetics, health and nutritional supplements, and household products through online direct sales, authorized stores, third-party merchants and live-stream marketing. Revenue was generated almost entirely in China and denominated in RMB.
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $210.0 million | $170.9 million |
| Cost of revenue | $203.7 million | $159.3 million |
| Gross profit and margin | $6.2 million; 3.0% | $11.7 million; 6.8% |
| Operating loss | $12.0 million; 5.7% of revenue | $7.0 million; 4.1% of revenue |
| Net loss attributable to ordinary shareholders | $11.5 million; $0.39 loss per share | $6.4 million; $0.26 loss per share |
| Operating cash flow | $(12.0) million | $(18.0) million |
Revenue mix in 2022 was cosmetics $99.3 million (47.3%), household products $70.6 million (33.6%), and health and nutritional supplements $39.9 million (19.0%).
Liquidity, debt and cash flow
- At year-end, cash was $13.7 million and restricted cash was $3.0 million; total cash and restricted cash was $16.7 million. The restricted deposit served as collateral for a bank loan.
- Working capital was $28.3 million. Current assets were $59.9 million and current liabilities were $31.6 million.
- Short-term bank borrowing was $2.46 million at year-end, bearing 4.6% interest; the company says it was repaid at maturity in March 2023. Operating lease liabilities totaled $3.28 million, including current and non-current portions.
- Investing cash outflow was $1.34 million; financing cash inflow was $9.94 million, primarily from 2022 ordinary-share issuances. Cash and restricted cash declined by $4.53 million during the year.
- Advances to suppliers rose to $21.7 million from $5.2 million. The company reported that by March 31, 2023, approximately $18.5 million, or 82%, of the year-end advances had been utilized. About 66% of year-end accounts receivable had also been collected by that date.
Material changes versus FY2021
- Revenue increased 22.9%, but cost of revenue rose 27.9%; gross margin fell from 6.8% to 3.0%, and the operating and net losses widened.
- Cosmetics revenue grew 25.9%, with higher average selling prices partly offset by fewer units sold. Household-products revenue grew 96.5%, reflecting higher prices and volumes. Health and nutritional supplements revenue declined 28.8%, including lower volume and reduced purchases by a major customer.
- Marketing expense decreased 6.2% to $8.8 million, while general and administrative expense increased 5.1% to $5.8 million. Fulfillment expense was $3.7 million, or 1.8% of revenue.
- Ordinary shares issued and outstanding increased from 25.68 million to 34.12 million. The company raised approximately $9.9 million through 2022 share offerings.
- Longrich Group, controlled by a major shareholder, represented about 14% of 2022 purchases, down from about 45% in 2021. A second supplier represented about 12% in 2022. One customer accounted for approximately 15.9% of 2022 sales.
Outlook, risks and unusual items
- Management stated that available cash, expected collections and utilization of supplier advances, and potential borrowing or equity financing should provide liquidity for at least 12 months from issuance of the financial statements. It also described a goal of moving from losses toward profitability over the next one to two years through cost reductions, including lower promotional and marketing spending. No quantified revenue or earnings guidance was provided.
- Management attributed the losses and cash outflow to its expansion strategy and increased emphasis on leading and premium brands, which raised product costs; working-capital needs also increased. COVID-related restrictions disrupted operations and marketing activity, particularly during 2022 and into January 2023, although the company said 2022 operations were not significantly negatively affected overall.
- Key risks include the VIE structure and uncertainty in PRC law and regulation; limits on moving cash out of China; supplier, customer and related-party concentration; competition and pricing pressure; product quality, liability and data-security exposure; RMB translation risk; and potential Nasdaq listing compliance issues. The company disclosed receiving a Nasdaq notice in December 2022 for falling below the $1.00 minimum bid-price requirement, with a stated compliance deadline of June 26, 2023.
- Management identified two material weaknesses in internal control over financial reporting: insufficient in-house U.S. GAAP and SEC-reporting expertise, and inadequate segregation of privileged access in the Yonyou accounting system. Management said controls were ineffective at year-end and described remediation plans; timely or successful remediation is not assured.
- Unusual items included $1.10 million of inventory write-downs, $1.85 million of share-based compensation, and a $2.45 million foreign-currency translation loss in other comprehensive income. The company reported no material legal proceedings. Its financial-statement auditor gave an unqualified opinion, but did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether margins and cash generation improve, given FY2022 gross margin of 3.0%, the widened net loss, and continued negative operating cash flow.
- Collection of receivables and use or recovery of supplier advances after March 31, 2023, including the remaining balances and any credit-loss provisions.
- Whether cash held in the PRC is accessible for group needs, and the status and terms of any borrowing or future financing.
- Progress in remediating the two material weaknesses and any subsequent auditor or control findings.
- Current Nasdaq bid-price compliance and the company’s regulatory filing obligations in China, including requirements affecting future offerings.
- Related-party purchasing and leasing terms, supplier and customer concentration, and any changes following the CEO transition effective March 1, 2023.